
InauguralInvitation Only
Pan-Oncology
USSummit 2027
Three days, 74 people, one room.
October 28 to 30, 2027
Scottsdale, AZ
Dates
October 28-30, 2027
Three-day program
Venue
Scottsdale, AZ
Hotel TBD
Audience
74 by invitation
36 KOLs & 38 fellows
Format
10 sessions · 40 talks
14 fellow-presented cases
Four Tumor Areas, One Room
The Summit convenes the faculty of four separate disease areas at the same table: 36 leading US oncology KOLs across breast, gastrointestinal, lung and genitourinary cancers, alongside 38 hand-selected fellows and junior faculty, for three days in Scottsdale.
Each tumor area runs its own block of dense, perspective-driven sessions. What no single-tumor meeting can offer sits between them: a Cross-Tumor pillar where the questions that cut across disease areas are argued by the people who lead each of them, and a Next Gen block built for the fellows in the room and led by all four chairs together.
For companies with assets in more than one tumor area, this is the only meeting in the portfolio where a single engagement reaches all of them.
Cross-TumorNext GenADC SequencingPerioperative & Adjuvant IOMRD & ctDNAHER2 Across TumorsRAS-Directed Therapy · Radioligand Therapy & PSMA PETBiomarker-Driven Selection · Cardio-Oncology
Summit Co-Chairs
Listed alphabetically by surname

Tanios Bekaii-Saab
Mayo Clinic, Phoenix, AZ

Virginia Kaklamani
UT Health, San Antonio, TX

Stephen Liu
Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.

Rana R. McKay
UC San Diego Health, CA
A Proven Platform, Not a One-Off
The Summit is part of a program of 21 meetings across the US and Europe, and brings faculty from our breast, lung, gastrointestinal and genitourinary cancer meetings together for the first time.
74
Invited attendees only, sustained access, not a crowd
4
Tumor areas in one room: breast, gastrointestinal, lung and genitourinary
21
Established meetings across the US and Europe, a proven platform
Pan-Oncology US Summit 2027
Confirmed Faculty
Listed alphabetically by surname
Neeraj Agarwal
Huntsman Cancer Institute, Salt Lake City, UT
Emmanuel Antonarakis
University of Minnesota Masonic Cancer Center, Minneapolis, MN
Tanios S. Bekaii-Saab
Mayo Clinic, Phoenix, AZ
Marcela Mazo Canola
UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Tina Cascone
MD Anderson Cancer Center, Houston, TX
Mariana Chavez-MacGregor
MD Anderson Cancer Center, Houston, TX
Yu-Wei Chen
UC San Diego Health, San Diego, CA
Cristina Ferrone
Cedars-Sinai Medical Center, Los Angeles, CA
Richard Finn
David Geffen School of Medicine at UCLA, Los Angeles, CA
Carla S. Fisher
Indiana University School of Medicine, Indianapolis, IN
Narjust Florez
Dana-Farber Cancer Institute, Boston, MA
Justin F. Gainor
Massachusetts General Hospital, Boston, MA
Matthew Galsky
Icahn School of Medicine at Mount Sinai, New York, NY
Marina Chiara Garassino
University of Chicago Medicine, Chicago, IL
Balazs Halmos
Montefiore Einstein Comprehensive Cancer Center, Bronx, NY
James J. Harding
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Y. Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Virginia Kaklamani
UT Health San Antonio, San Antonio, TX
Samuel J. Klempner
Massachusetts General Hospital, Boston, MA
Kate I. Lathrop
UT Health San Antonio, San Antonio, TX
Stephen Liu
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Christine M. Lovly
City of Hope National Medical Center, Duarte, CA
Heather McArthur
UT Southwestern Medical Center, Dallas, TX
Bradley McGregor
Dana-Farber Cancer Institute, Boston, MA
Rana R. McKay
UC San Diego Health, San Diego, CA
Shanu Modi
Memorial Sloan Kettering Cancer Center, New York, NY
Todd M. Morgan
University of Michigan Rogel Cancer Center, Ann Arbor, MI
Mamta Parikh
UC Davis Comprehensive Cancer Center, Sacramento, CA
Sonya Reid
Vanderbilt-Ingram Cancer Center, Nashville, TN
Julia Rotow
Dana-Farber Cancer Institute, Boston, MA
John H. Strickler
Duke University School of Medicine, Durham, NC
Alexandra Thomas
Duke Cancer Institute, Durham, NC
Phuoc T. Tran
MD Anderson Cancer Center, Houston, TX
Brian M. Wolpin
Dana-Farber Cancer Institute, Boston, MA
Christina S. Wu
Mayo Clinic, Phoenix, AZ
Further faculty to be announced
Three Days, Ten Sessions
Proposed Agenda
15 min
5 min
30 min
20 min
65 min
Day One · Thursday, October 28, 2027 · Genitourinary & Breast
Session IGenitourinary Cancers
ModeratorTBC
Metastatic APMR: Treatment Selection by Prior Therapy Exposure, PARP Combinations, Radioligand Therapy, Taxanes, and Biomarker Testing
Emmanuel AntonarakisUniversity of Minnesota Masonic Cancer Center, Minneapolis, MN
Localized Prostate Cancer: Risk Stratification, Selecting Among Definitive Treatment Options, and Who Benefits from Intensification
Todd M. MorganUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI
Biochemical Recurrence: Imaging-First Evaluation with PSMA PET, Metastasis-Directed Therapy, and When to Start Systemic Therapy
Phuoc T. TranMD Anderson Cancer Center, Houston, TX
Metastatic APMS: Doublets, Triplets, and Tailoring Intensification to Volume and Biology
Neeraj AgarwalHuntsman Cancer Institute, Salt Lake City, UT
Panel Discussion
Coffee Break
Session IIGenitourinary Cancers
ModeratorTBC
Advanced Clear Cell RCC: Frontline IO Combinations, Sequencing After Progression, and HIF-2α Inhibition
Yu-Wei ChenUC San Diego Health, San Diego, CA
Localized and Locally Advanced RCC: Risk Stratification and Adjuvant Therapy Decisions
Bradley McGregorDana-Farber Cancer Institute, Boston, MA
Muscle Invasive Bladder Cancer: Perioperative and Bladder Sparing Strategies
Matthew GalskyIcahn School of Medicine at Mount Sinai, New York, NY
Metastatic Urothelial Carcinoma: Enfortumab Vedotin–Pembrolizumab, ADC Sequencing, and Toxicity Management
Mamta ParikhUC Davis Comprehensive Cancer Center, Sacramento, CA
Panel Discussion
Session IXBreast Cancer
ModeratorTBC
Cardio-Oncology: How to Evaluate the Heart
Alexandra ThomasDuke Cancer Institute, Durham, NC
Optimal Treatment of High Risk HR+ Early Breast Cancer
Sonya ReidVanderbilt-Ingram Cancer Center, Nashville, TN
The Evolving Landscape of Metastatic HR+ Breast Cancer
Kate I. LathropUT Health San Antonio, San Antonio, TX
Omitting Axillary Surgery: Pushing the Limits
Carla S. FisherIndiana University School of Medicine, Indianapolis, IN
Panel Discussion
Coffee Break
Session XBreast Cancer
ModeratorTBC
Updates in Immunotherapy in the Treatment of Breast Cancer
Heather McArthurUT Southwestern Medical Center, Dallas, TX
Should We Incorporate Maintenance Therapy in HER2+ MBC?
Mariana Chavez-MacGregorMD Anderson Cancer Center, Houston, TX
ADCs: How Can We Improve on What We Already Have?
Shanu ModiMemorial Sloan Kettering Cancer Center, New York, NY
The Optimal Treatment of Early Stage HER2+ Breast Cancer
Marcela Mazo CanolaUT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
Panel Discussion
Day Two · Friday, October 29, 2027 · Cross-Tumor & Next Gen
Agenda & Faculty to be Announced
Day Three · Saturday, October 30, 2027 · Gastrointestinal & Lung
Session IIIGastrointestinal Cancers
ModeratorTBC
The Many Ways for Targeting RAS in Pancreas Cancer
Brian M. WolpinDana-Farber Cancer Institute, Boston, MA
Perioperative Strategies in Early Stage Pancreas Cancer: An Evolving Landscape
Cristina FerroneCedars-Sinai Medical Center, Los Angeles, CA
HER2 as a Target in Gastroesophageal Cancer: First Line and Sequencing Strategies
Samuel J. KlempnerMassachusetts General Hospital, Boston, MA
Perioperative Strategies in Gastroesophageal Cancer: Who and What?
Yelena Y. JanjigianMemorial Sloan Kettering Cancer Center, New York, NY
Panel Discussion
Coffee Break
Session IVGastrointestinal Cancers
ModeratorTBC
The Evolution of the Treatment Landscape of Patients with Biliary Tract Cancers
James J. HardingMemorial Sloan Kettering Cancer Center, New York, NY
Perioperative Strategies in Early Stage MSI-H Colon and Rectal Cancers
Christina S. WuMayo Clinic, Phoenix, AZ
The Rise of Targeted Therapies in First Line Treatment of mCRC
John H. StricklerDuke University School of Medicine, Durham, NC
The Role of Systemic Therapeutic Strategies in Unresectable Embolization Eligible HCC
Richard FinnDavid Geffen School of Medicine at UCLA, Los Angeles, CA
Panel Discussion
Session VIILung Cancer
ModeratorTBC
Evolving Standards in Perioperative Immunotherapy for NSCLC
Tina CasconeMD Anderson Cancer Center, Houston, TX
Rewriting Paradigms: Best Practice for Advanced SCLC
Balazs HalmosMontefiore Einstein Comprehensive Cancer Center, Bronx, NY
Immunotherapy in Advanced NSCLC: The Case For/Against Bispecific Antibodies
Marina Chiara GarassinoUniversity of Chicago Medicine, Chicago, IL
ADCs in Driver Negative NSCLC: The Path Forward
Speaker TBC
Panel Discussion
Coffee Break
Session VIIILung Cancer
ModeratorTBC
Crafting Best Strategies for NSCLC with HER2 Mutation or Overexpression
Julia RotowDana-Farber Cancer Institute, Boston, MA
Building on Success: Optimizing Care for ALK and ROS1 NSCLC Across Stages
Narjust FlorezDana-Farber Cancer Institute, Boston, MA
How to Best Sequence Therapies for NSCLC with a Common EGFR Mutation
Justin F. GainorMassachusetts General Hospital, Boston, MA
Treating Advanced NSCLC with EGFR Exon 20 Insertion
Christine M. LovlyCity of Hope National Medical Center, Duarte, CA
Panel Discussion
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →

